CYTL1 (Cytokine Like 1)

Enrichment analysis implicated key biological processes, including kinase signaling, cell cycle regulation, and microRNA pathways involved in apoptosis and oncogenesis. This study reveals novel differential DNA methylation patterns associated with EOS in the Chinese population and identifies key biological pathways potentially underlying its pathogenesis.

This study identifies CYTL1 and H6PD as key regulators of tumor metabolism in mesothelioma. CYTL1 is a promising therapeutic target, warranting further investigation, while H6PD remains a potential candidate despite unfavorable docking results. These findings demonstrate the value of multi-omics approaches in identifying novel therapeutic targets for mesothelioma.

A gene signature with 9 CARMRs was developed in our study, which served as biomarkers for PCa. This brings benefits in determining the prognosis of patients with PCa and guiding personalized treatment.

We demonstrate that Ewing sarcoma depends on C4orf48, which functions as a cofactor for NELL2, a cytokine we previously identified as a critical dependency in Ewing sarcoma. These results reveal C4orf48 as a targetable dependency that links FAT4 - Hippo signaling and NELL2 signaling in Ewing sarcoma.

T2DM is associated with reduced GC risk. The risk score and model may help guide GC prognosis and management.

In summary, we constructed and validated a five-gene signature related to M2 macrophages, which shows strong potential for forecasting bladder cancer prognosis and immunotherapy response.

We have effectively discerned pivotal genes from the endothelial cell perspective and constructed an EPI for BC patients, thereby offering promising prospects for precision medicine.

This study not only presents a novel prognostic marker but also carves out potential avenues for immunotherapy and targeted therapeutic strategies in BLCA. By demystifying the profound impact of immune-related genes and the tumor immune environment, this study augments the comprehension and prognostic management of bladder cancer.

Silencing CBS counteracted CYTL1-mediated ferroptosis resistance. Our results show the importance of exogeneous cysteine in breast cancer cells with low CYTL1 expression and highlight a potential metabolic vulnerability to target.

This study analyzed the tumor ecosystem of primary and metastatic UM, providing a metastasis-related model that could be used to evaluate the prognosis, risk of metastasis, immunotherapy, and efficacy of antineoplastic drug treatment of UM.

In vitro experiments further confirmed that the knockdown of CYTL1 significantly inhibited the migration and invasive ability of melanoma cells. CYTL1 is a valuable prognostic biomarker and a potentially effective therapeutic target in melanoma, especially BRAF-mutated melanoma.

Our study demonstrated that m6APR_Score and CD83, NRIP1, ACSL1, METTL7B, OGT, and C4orf48 potentially provided novel and promising prognostic support for AML patients.